FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR EUCRISA

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Eucrisa Instructions, F-02572A. Providers may refer to the Forms page of the ForwardHealth Portal at https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Eucrisa form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION

1. Name – Member (Last, First, Middle Initial)

2. Member ID Number	3. Date of Birth – Member						
SECTION II – PRESCRIPTION INFORMATION							
4. Drug Name	5. Drug Strength						
6. Date Prescription Written	7. Directions for Use						
8. Name – Prescriber		9. National Provider Identifier – Prescriber					
10. Address – Prescriber (Street, City, State, Zip+4 Code)							
11. Phone Number – Prescriber							
SECTION III – CLINICAL INFORMATION							
12. Diagnosis Code and Description							
13. Does the member have atopic dermatitis?		🗅 Yes 🗖 No					
14. Has the member used a topical steroid for at least two c experienced an unsatisfactory therapeutic response?	ths and 🔲 Yes 🔲 No						

If yes, list the name and strength of the topical steroid, specific details about the unsatisfactory therapeutic response, and the approximate dates that the topical steroid was taken in the space provided.



15. Has the member used a topical ster adverse drug reaction?	oid and experienced a	clinically sigr	ificant		Yes		No		
If yes, list the name and strength of the topical steroid, specific details about the significant adverse drug reaction, and the approximate dates that the topical steroid was used in the space provided.									
16. Has the member used Elidel or Protopic for at least two consecutive mo and experienced an unsatisfactory therapeutic response?			onths		Yes		No		
If yes, list the name and strength of the drug used, specific details about the unsatisfactory therapeutic response, and the approximate dates that Elidel or Protopic was used in the space provided.									
17. Has the member used Elidel or Prot	topic and experienced a	a clinically sic	inificant						
adverse drug reaction?			innount		Yes		No		
If yes, list the name of the drug used, the strength, specific details about the significant adverse drug reaction, and the approximate dates that Elidel or Protopic was used in the space provided.									
SECTION IV – AUTHORIZED SIGNATURE									
18. SIGNATURE – Prescriber			19. Date Signed						
			C C						
SECTION V – FOR PHARMACY PROVIDERS USING STAT-PA									
20. National Drug Code (11 Digits)	21. Days' Supply Requested (Up to 365 Days)								
22. National Provider Identifier									
23. Date of Service (mm/dd/ccyy) (For STAT-PA requests, the date of service may be up to 31 days in the future or up to 14 days in the past.)									
24. Place of Service									
25. Assigned PA Number									
26. Grant Date	27. Expiration Date		28. Number of Days Approved						

SECTION VI - ADDITIONAL INFORMATION

29. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may also be included here.